{
    "clinical_study": {
        "@rank": "60367", 
        "arm_group": {
            "arm_group_label": "GERD Los Angeles A and B", 
            "arm_group_type": "Other", 
            "description": "Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily"
        }, 
        "brief_summary": {
            "textblock": "To investigate the impact of initial treatment duration (4-week versus 8-week)of\n      Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in\n      patients with symptomatic erosive esophagitis"
        }, 
        "brief_title": "Rate of Complete Symptom Relief, Prevention of Symptom Relapse and Maintenance: Grades A and B Esophagitis of Esomeprazole Therapy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Erosive Esophagitis", 
        "condition_browse": {
            "mesh_term": "Esophagitis"
        }, 
        "detailed_description": {
            "textblock": "Patients:\n\n      Patients between the ages of 15 and 80 years with clinical symptoms of acid regurgitation,\n      heart burn, or feeling of acidity in the stomach, who have Los Angeles Grade A and B erosive\n      esophagitis proven by endoscopy are recruited. Criteria for exclusions include (1)\n      coexistence of peptic ulcer or gastrointestinal malignancies, (2) pregnancy, (3) coexistence\n      of serious concomitant illness (for example, decompensated liver cirrhosis and uremia), (4)\n      previous gastric surgery, (5) allergy to esomeprazole, (6) symptom score of a validated\n      questionnaire (Chinese GERDQ) less than 12, and (7) equivocal endoscopic diagnosis of Los\n      Angeles Grade A and B erosive esophagitis.\n\n      Outcome parameters:\n\n      The main outcome measures\n\n        1. Rate of complete symptom relief (CSR) at the end of initial treatment phase\n\n        2. rate of symptom relapse within 12 weeks after stopping initial therapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients between the ages of 15 and 80 years\n\n          -  with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in\n             the stomach,\n\n          -  who have Los Angeles Grade A and B erosive esophagitis proven by endoscopy are\n             recruited.\n\n        Exclusion Criteria:\n\n          1. coexistence of peptic ulcer or gastrointestinal malignancies,\n\n          2. pregnancy,\n\n          3. coexistence of serious concomitant illness (for example, decompensated liver\n             cirrhosis and uremia),\n\n          4. previous gastric surgery,\n\n          5. allergy to esomeprazole,\n\n          6. symptom score of a validated questionnaire (Chinese GERDQ) less than 12, and\n\n          7. equivocal endoscopic diagnosis of Los Angeles Grade A and B erosive esophagitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874535", 
            "org_study_id": "GERD A and B"
        }, 
        "intervention": {
            "arm_group_label": "GERD Los Angeles A and B", 
            "description": "Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis", 
            "intervention_name": "Esomeprazole 40 mg", 
            "intervention_type": "Drug", 
            "other_name": "Nexium 40mg"
        }, 
        "intervention_browse": {
            "mesh_term": "Omeprazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "chuahsk@seed.net.tw", 
                "last_name": "Seng-Kee Chuah, M.D.", 
                "phone": "886-7-7317123", 
                "phone_ext": "8301"
            }, 
            "contact_backup": {
                "email": "luketai1019@gmail.com", 
                "last_name": "Wei-Chen Tai, M.D.", 
                "phone": "886-7-7317123", 
                "phone_ext": "8301"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung City", 
                    "country": "Taiwan", 
                    "zip": "833"
                }, 
                "name": "Seng-Kee Chuah"
            }, 
            "investigator": {
                "last_name": "Seng-Kee Chuah, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis", 
        "overall_contact": {
            "email": "chuahsk@seed.net.tw", 
            "last_name": "Seng-Kee Chuah, M.D.", 
            "phone": "886-7-7317123", 
            "phone_ext": "8301"
        }, 
        "overall_contact_backup": {
            "email": "luketai1019@gmail.com", 
            "last_name": "Wei-Chen Tai, M.D.", 
            "phone": "886-7-7317123", 
            "phone_ext": "8301"
        }, 
        "overall_official": {
            "affiliation": "Kaohsiung  Chang Gung Memorial Hospital, Taiwan", 
            "last_name": "Seng-Kee Chuah, M.D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of complete symptom relief (CSR) at the end of initial treatment phase", 
            "measure": "The Rates of Complete Symptom Relief", 
            "safety_issue": "No", 
            "time_frame": "20  weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874535"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chang Gung Memorial Hospital", 
            "investigator_full_name": "luketai1019", 
            "investigator_title": "Attending physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Rate of symptom relapse within 12 weeks after stopping initial therapy", 
            "measure": "The Rate of Symptom Relapse", 
            "safety_issue": "No", 
            "time_frame": "12  weeks"
        }, 
        "source": "Chang Gung Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chang Gung Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}